company background image
NOVO B logo

Novo Nordisk CPSE:NOVO B Stock Report

Last Price

kr.819.70

Market Cap

kr.3.7t

7D

-3.9%

1Y

63.1%

Updated

29 Feb, 2024

Data

Company Financials +

NOVO B Stock Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

NOVO B fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance6/6
Financial Health4/6
Dividends3/6

Novo Nordisk A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Pricekr.819.70
52 Week Highkr.861.50
52 Week Lowkr.476.05
Beta0.18
1 Month Change9.56%
3 Month Change17.32%
1 Year Change63.12%
3 Year Change277.09%
5 Year Change400.81%
Change since IPO30,315.60%

Recent News & Updates

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30
Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Recent updates

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30
Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Dec 12
Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Nov 24
Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Aug 20
Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

May 22
Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

May 04
These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Novo Nordisk (CPH:NOVO B) Will Pay A Larger Dividend Than Last Year At DKK8.15

Feb 04
Novo Nordisk (CPH:NOVO B) Will Pay A Larger Dividend Than Last Year At DKK8.15

Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Feb 02
Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jan 15
Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Oct 29
Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 38% Undervalued

Oct 11
An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 38% Undervalued

With EPS Growth And More, Novo Nordisk (CPH:NOVO B) Makes An Interesting Case

Aug 24
With EPS Growth And More, Novo Nordisk (CPH:NOVO B) Makes An Interesting Case

Shareholder Returns

NOVO BDK PharmaceuticalsDK Market
7D-3.9%0.7%-0.004%
1Y63.1%13.0%27.6%

Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned 13% over the past year.

Return vs Market: NOVO B exceeded the Danish Market which returned 27.6% over the past year.

Price Volatility

Is NOVO B's price volatile compared to industry and market?
NOVO B volatility
NOVO B Average Weekly Movement2.9%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.6%
10% most volatile stocks in DK Market9.9%
10% least volatile stocks in DK Market2.5%

Stable Share Price: NOVO B has not had significant price volatility in the past 3 months.

Volatility Over Time: NOVO B's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192363,845Lars Jorgensenhttps://www.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVO B fundamental statistics
Market capkr.3.72t
Earnings (TTM)kr.83.68b
Revenue (TTM)kr.232.26b

43.7x

P/E Ratio

15.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVO B income statement (TTM)
Revenuekr.232.26b
Cost of Revenuekr.35.77b
Gross Profitkr.196.50b
Other Expenseskr.112.81b
Earningskr.83.68b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)18.75
Gross Margin84.60%
Net Profit Margin36.03%
Debt/Equity Ratio20.0%

How did NOVO B perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

50%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.